UC Davis has experienced exceptional growth of our research team and our involvement in clinical trials over the past few years. Our research includes inpatient and outpatient studies focusing on viral hepatitis, liver diseases and their complications, gastrointestinal disorders, and diagnostic and therapeutic procedures. Our trials are supported by the National Institute for Health, the pharmaceutical industry and UC Davis Health through investigator-initiated projects.

We have participated in national and international studies for the approval of new medications such as Terlipressin, a novel drug to treat a severe kidney condition associated with end-stage liver disease, and N-acetyl-cystein for the treatment of non-acetaminophen induced acute liver failure, and new drugs for the treatment of hepatitis B and C. Currently we are the top-enrolling site in the continental United States for a Phase II study on the use of Polymerase inhibitor in combination with the standard treatment for chronic hepatitis C.

In 2007 we moved our operations to a premier facility in midtown Sacramento located conveniently near U.S. Highway 50 and Interstate 80, providing easy access and free parking. Our team includes physicians, clinical research coordinators, a nurse practitioner, and student volunteers. Our goal is to provide a welcoming environment and personalized care, in addition to following ethical conduct of research and best practice guidelines.

For more information, please contact:

Sandeep Dhaliwal
UC Davis Health
Ticon I Building
2000 Stockton Boulevard, Suite 100 
Sacramento, CA 95817
Phone: 916-734-8696
FAX: 916-734-8666
e-mail: sandhaliwal@ucdavis.edu